Acer MedicalROCO:6857 +1.39%52 Altman Z-Score is 19.85 as of Jul. 09, 2026, which is 36% below its 10-year median of 31.10. GuruFocus rates ROCO:6857 with a GF Score™ of 52/100 and a GF Value™ of NT$262.76 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Acer Medical ranks better than 96.22% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 19.85 is strong.
Acer Medical has a Altman Z-Score of 19.85, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Acer Medical's Altman Z-Score or its related term are showing as below:
ROCO:6857'
s Altman Z-Score Range Over the Past 10 Years
Min: 19.85 Med: 31.1 Max: 44.96
Current: 19.85
During the past 7 years, Acer Medical's highest Altman Z-Score was 44.96. The lowest was 19.85. And the median was 31.10.
Acer Medical (ROCO:6857) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Acer Medical Altman Z-Score Related Terms
Acer Medical Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Acer Medical's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6857 vs VEEV, BTSG, TEM: Altman Z-Score Comparison
For the Health Information Services subindustry, Acer Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Medical Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Acer Medical's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Acer Medical's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.763
+
1.4
*
-0.9224
+
3.3
*
-0.1432
+
0.6
*
34.0131
+
1.0
*
0.2898
=
19.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Acer Medical (ROCO:6857) has a Altman Z-Score of 19.85 as of Jul. 09, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Acer Medical and its competitors. This is 36% below median its historical median of 31.10. Over the past decade, Acer Medical's Altman Z-Score has ranged from 19.85 to 44.96. According to the industry distribution chart, Acer Medical ranks #25 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 3.8%.
Is Acer Medical's Altman Z-Score too high?
Acer Medical's current Altman Z-Score of 19.85 is 36% below median its 10-year median of 31.10. Over the past 10 years, this metric has ranged from a low of 19.85 to a high of 44.96. The Healthcare Providers & Services industry median Altman Z-Score is 2.45. Acer Medical's value of 19.85 is 710.2% above this industry median. Based on the distribution chart, Acer Medical ranks #25 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Acer Medical has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's Altman Z-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #25 out of 662 companies for Altman Z-Score. This places Acer Medical in the top 4% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.45. Acer Medical's value of 19.85 is 710.2% above this benchmark. Historically, Acer Medical's own Altman Z-Score has ranged from 19.85 to 44.96 over the past decade. While the company's 10-year median is 31.10 vs. the industry median of 2.45, Acer Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.45, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acer Medical's current Altman Z-Score of 19.85 is 710.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current Altman Z-Score is 19.85, which is 36% below median its own 10-year median of 31.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$262.76, compared to a current price of NT$94.50 — trading 64% below its estimated fair value. The current Altman Z-Score is 19.85, which is 36% below median its 10-year median of 31.10 and 710.2% above the Healthcare Providers & Services industry median of 2.45. Acer Medical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current Altman Z-Score is 19.85 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$94.50 is trading 64% below its estimated GF Value™ of NT$262.76.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
Altman Z-Score: 19.85 (36% below median its 10-year median of 31.10)
GF Value™: NT$262.76 vs. price of NT$94.50 (64% below fair value)
Industry Position: 710.2% above the Healthcare Providers & Services median (#25 of 662)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
52GF Score
Get the complete analysis for ROCO:6857
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
